Literature DB >> 30307786

Prognostic utility of circulating nucleic acids in acute brain injuries.

Andrea Regner1,2, Lindolfo da Silva Meirelles1,2, Nilo Ikuta2, Andre Cecchini1,2,3, Daniel Simon1,2.   

Abstract

INTRODUCTION: Acute brain injuries represent major causes of morbidity and mortality worldwide. Nevertheless, therapeutic options are centered mainly on supportive care, and accurate prognosis prediction following traumatic brain injury (TBI) or stroke remains a challenge in clinical settings. Areas covered: Circulating DNA and RNA have shown potential as predictive molecules in acute brain injuries. In particular, plasma cell-free DNA (cfDNA) levels have been correlated to severity, mortality, and outcome after TBI and stroke. The real-time quantitative polymerase chain reaction (qPCR) is the most widely used technique for determination of cfDNA in brain injuries; however, to consider the use of cfDNA in emergency settings, a quicker and easier methodology for detection should be established. A recent study proposed detection of cfDNA applying a rapid fluorescent test that showed compatible results with qPCR. Expert commentary: As a promising perspective, detection of cfDNA levels using simple, rapid, and cheap methodology has potential to translate to clinic as a point-of-care marker, supporting the clinical decision-making in emergency care settings. Conversely, miRNA profiles may be used as signatures to determine the type and severity of injuries. Additionally, in the future, some miRNAs may constitute innovative neurorestorative therapies without the common hurdles associated with cell therapy.

Entities:  

Keywords:  Acute brain injury; cell-free DNA; microRNA; nucleic acids; prognosis; stroke; traumatic brain injury

Mesh:

Substances:

Year:  2018        PMID: 30307786     DOI: 10.1080/14737159.2018.1535904

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN: 1473-7159            Impact factor:   5.225


  7 in total

Review 1.  Biomarkers for traumatic brain injury: a short review.

Authors:  Marcela Usberti Gutierre; João Paulo Mota Telles; Leonardo Christiaan Welling; Nícollas Nunes Rabelo; Manoel Jacobsen Teixeira; Eberval Gadelha Figueiredo
Journal:  Neurosurg Rev       Date:  2020-10-19       Impact factor: 3.042

2.  Liquid biopsy markers for stroke diagnosis.

Authors:  Harshani Wijerathne; Malgorzata A Witek; Alison E Baird; Steven A Soper
Journal:  Expert Rev Mol Diagn       Date:  2020-07-05       Impact factor: 5.225

3.  Comparison of paired cerebrospinal fluid and serum cell-free mitochondrial and nuclear DNA with copy number and fragment length.

Authors:  Aolong Chen; Jun Li; Lei Wang; Qin Huang; Jiajin Zhu; Shumeng Wen; Jianxin Lyu; Wenhe Wu
Journal:  J Clin Lab Anal       Date:  2020-02-13       Impact factor: 2.352

4.  Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study.

Authors:  Dorte Schou Nørøxe; Olga Østrup; Christina Westmose Yde; Lise Barlebo Ahlborn; Finn Cilius Nielsen; Signe Regner Michaelsen; Vibeke Andrée Larsen; Jane Skjøth-Rasmussen; Jannick Brennum; Petra Hamerlik; Hans Skovgaard Poulsen; Ulrik Lassen
Journal:  Oncotarget       Date:  2019-07-09

5.  A Clinical Predictive Nomogram for Traumatic Brain Parenchyma Hematoma Progression.

Authors:  Jiangtao Sheng; Weiqiang Chen; Dongzhou Zhuang; Tian Li; Jinhua Yang; Shirong Cai; Xiaoxuan Chen; Xueer Liu; Fei Tian; Mindong Huang; Lianjie Li; Kangsheng Li
Journal:  Neurol Ther       Date:  2021-12-02

6.  Cell-Free Mitochondrial DNA in Acute Brain Injury.

Authors:  Saeed Kayhanian; Angelos Glynos; Richard Mair; Andras Lakatos; Peter J A Hutchinson; Adel E Helmy; Patrick F Chinnery
Journal:  Neurotrauma Rep       Date:  2022-09-28

7.  Prognostic utility of early plasma matrix metalloproteinases -2 and -9 concentrations after severe traumatic brain injury.

Authors:  Rosane de Lima; Daniel Simon; Willy Deivson Leandro da Silva; Débora Dreher Nabinger; Andrea Regner
Journal:  Rev Bras Ter Intensiva       Date:  2020 Jul-Sep
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.